NIMR

Ongoing Projects

# Project Title Lead Lead Centre Funder Budget Funding Duration
1
Expansion of Antimicrobial Resistance Surveillance (AMR) in Tanzania (Expand AMR)
John Lusingu
NIMR Tanga
Global Health Protection Programme (GHP)
€400,000
03/2023 to 02/2026
2
Strengthening environmental surveillance to advance public health action
Vito Baraka
NIMR Tanga
EDCTP3
€525,800.00
04/2023 to 03/2026
3
Severe Malaria treatment with Rectal artesunate and Artemisinin-based Combination Therapy [in remote settings]. (Acronym: SEMA ReACT).
Vito Baraka
NIMR Tanga
EDCTP3
€231,645.00
04/2023 to 03/2027
4
Climate Change and its Adverse Effects on the double burden of Malnutrition and Infectious Diseases among women of reproductive age in northeastern Tanzania
Daniel Minja
NIMR Tanga
Danida
DKK 3,000,000
01/2024 to 12/2027
5
Building resilient research ethics, Diagnostics and medicines regulatory capacity during routine and public health emergency periods (BREEDIME).
Elias Nyanda
NIMR Mbeya/NIMR Muhimbili
EDCTP3
€ 599 637.50.
1st June 2023 – 31st May 2026
6
A Phase IIb, Open-Label, Randomized Controlled Dose Ranging Multi-Centre Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-Response Relationship of different doses of BTZ-043 in combination with Bedaquiline and Delamanidin in Adult Subjects with Newly Diagnosed, Uncomplicated, Drug-sensitive Pulmonary Tuberculosis (DECISION Trial)
Lilian T Minja
NIMR Mbeya
The German Ministry for Education and Research (BMBF) and The Innovative Medicines Initiative (IMI)
€ 12,000 per patient
2023- 2025
7
Medical and Environmental Anthropology for 21st Century East Africa
Peter Mangesho
NIMR Amani
NORAD
Norwegian Krone 20,000,000
Jan 2021 – Dec 2026.
8
Entomological evaluation by pool screening (o-150 PCR) to demonstrate the interruption of onchocerca volvulus transmission in stopping of ivermectin mass drug administration
Akili Kalinga
NIMR Headquarters
African Field Epidemiology Network (AFENET/CDC)
Jan 2021–Dec 2025
9
Evaluation of OV16 ELISA serological prevalence of ≤2% in stopping mass drug administration (MDA) in Onchocerciasis elimination
Akili Kalinga
NIMR Headquarters
AFENET/CDC
$ 112,000
Jan 2021–Dec 2025
10
Suspected artemisinin resistance in Africa: Tracking its Emergence and Evolution in Tanzania, Rwanda, Uganda, and the Democratic Republic of Congo
Deus Ishengoma
NIMR Headquarters
National Institute of Health
$121,825
2021-2025
11
Decentralized sequencing for infectious disease surveillance in Tanzania [SEQ-TZ]
Lucas Matemba
NIMR Dodoma
DANIDA
TZS 4,158,537
2021–2025
12
Implementation of Hydrocele Surgeries in Tanzania
Lucas Matemba
NIMR Dodoma
ENDFUND Foundation
TZS 38,078,110
2022-2024
13
The National Malaria Vector Entomology Surveillance (MVES)
William Kisinza
NIMR Amani
Ministry of Health, Tanzania NMCP
TZS 1,209,262,880.00
2023 – 2025
14
Insecticidal efficacy, physical degradation and fabric integrity of the standard pyrethroid long lasting insecticide treated nets (LLINs) and new generation (Piperonyl
William Kisinza
NIMR Amani
Global fund through Ministry of Health, Tanzania NMCP
TZS. 120,960,000.00
Jan 2023 – Dec 2024.
15
Optimizing Childhood TB Treatment Decision Algorithms in Sub-Saharan Africa(OPTIC_TB)
Sayoki Godfrey Mfinanga
NIMR Muhimbili
Global Health EDCTP3
€3,999,998
March 2024 – Feb 2028
16
An exploration of the Karl Braun Collection and the Role of the Amani Institute during the German Colonial Period in Tanzania
William Kisinza
NIMR Amani
German Lost Art Foundation’s
€ 346.500,00
Jun 2022 – September 2025.
17
Analysis of the Insecticide Chemical Content in the Long Lasting Insecticidal Nets (LLINs) used for mosquito control in Tanzania
William Kisinza
NIMR Amani
Global funds through the Ministry of Health Tanzania/NMCP
€ 362,880.00
Jan 2023 – Dec 2025
18
Safety and health outcomes associated with NIMREGENIN among Cancer patients receiving care at the selected Consultant Hospitals in Tanzania – An Observational Cohort Study
Godfather Kimaro
NIMR Muhimbili
Ministry of Health Tanzania
TZS. 430,143,000.00
April 2023 – June 2025
19
Predicting Vector-Borne Disease epidemics: Dissemination of risk forecasting using District Health Information Software 2 in Tanzania (Acronym: PreVBD).
Vito Baraka
NIMR Tanga
DANIDA
Danish Krone 11,995,368
June 2020 to May 2025
20
Epilepsy Pathway Innovation in Africa (EPInA)
Bruno Mmbando
NIMR Tanga
University of Oxford
£580,866.00
Nov 2020 to Oct 2024
21
A multi-centre randomised controlled non-inferiority trial to compare the efficacy, safety and tolerability of Triple Artemisinin-based Combination Therapies versus first-line ACTs + placebo for the treatment of uncomplicated Plasmodium falciparum malaria in Africa ACRONYM: DeTACT-AFRICA study
John Lusingu
NIMR Tanga
UKAid
£344,166.25
Mar 2022 to Feb 2025
22
Evaluation of molecular point-of-care Xpert® Xpress SARS-CoV-2 detection implementation in resource limited settings. ACRONYM: EXPERT-CoV2
Daniel Minja
NIMR Tanga
EDCTP
Euro 500,000.00
Jan 2022 to Dec 2024
23
Convenience and cost-aspects of a new 1-STEP reconstitution injectable artesunate compared to conventional 2-STEP injectable artesunate for the treatment of severe falciparum malaria: a multi-centre study.
Samwel Gesase
NIMR Tanga
Shanghai Fosun Pharmaceuticals
$214,218.00
June 2022 to Sept 2024
24
Fluconazole plus flucytosine vs. fluconazole alone for cryptococcal antigen-positive patients identified through screening: A phase III randomized controlled trial. EFFECT TRIAL
Sayoki Mfinanga
NIMR Muhimbili
St George’s, University, London
GP 877,126
Jan 2021 to December 2024
25
The Impact of HIV infection on cancer treatment toxicity, tolerability, and survival among lung cancer patients in Tanzania; a prospective cohort study
Clara Lubinza
NIMR Muhimbili
NIH through the National Cancer Institute – early career-building grant
USD 40,000
July 2022 to June 2023, Extended to September 2024
26
a. A randomised placebo-controlled double-blind phase III trial to determine the effects of metformin versus placebo on the incidence of diabetes in HIV-infected persons with pre-diabetes in Tanzania. Metformin Treatment for Africa (META 3 trial)
Sayoki Mfinanga
NIMR Muhimbili
EDCTP
Euros 1,830,918
Oct 2020 to Sep 2024
27
Controlling chronic diseases in Africa: development and evaluation of integrated community-based management for HIV-infection, diabetes and hypertension in Tanzania and Uganda
Sayoki Mfinanga
NIMR Muhimbili
NIHR Global Health Policy
£ 1,015,449
Sep 2020 to Aug 2024
28
Lung cancer in East Africa in relation to HIV-1 infection: Epidemiological, Molecular characterization and Imaging (U54 Study
Sayoki Mfinanga
NIMR Muhimbili
National Institute of Health
USD 550,000
Sept 2020 – Aug 2025
29
Use of Point of Care HIV Viral Load Monitoring to Improve Viral Load Suppression among Children and Adolescents Living with HIV in East Africa
Senkoro Mbazi
NIMR Muhimbili
EDCTP
Euro 357,375
March 2021 to February 2025
30
Tanzania Global Health Security Priorities – Advancing Efforts and Strategies to Protect and Improve Health Security (TAGHESP)
Said Aboud
Tanzania Global Health Security Priorities – Advancing Efforts and Strategies to Protect and Improve Health Security (TAGHESP)
NIMR Muhimbili
USD 100,000.
Sept 2020 to Sept 2025
31
“Chanjo Kwa Wakati” – Leveraging community health workers and a responsive digital health system to improve vaccination coverage and timeliness in resource-limited settings
Esther Ngadaya
NIMR Muhimbili
U.S. National Institutes of Health (NIH)
USD 888,769
September 2022 to September 2027
32
Assessment of the feasibility of Involving Community Health Workers in the Delivery of Tuberculosis Preventive Treatment with Family Approach Under Programmatic Conditions in Tanzania.
Andrew Kilale
NIMR Muhimbili
MoH, Tanzania
TZS 1,047,615,000
January 2023 to September 2024
33
Addressing neonatal mortalities through Prolonged Immediate Kangaroo Mother Care in Bagamoyo Tanzania
Edna Majaliwa
NIMR Muhimbili
Laerdal foundation
USD 39,720
April 2023 to December 2024
34
A Phase IIb three-arm, two-stage HIV prophylactic vaccine trial with a second randomisation to compare TAF/FTC to TDF/FTC as pre-exposure prophylaxis.
Lucas Maganga
NIMR Mbeya
EDCTP2, Gilead Sciences plc
Euro 2,233,221.95
2018 – 2024
35
A Multisite, Phase 1/2a, double-blinded Randomized Controlled, Trial to Assess Safety, Tolerability and Immunogenicity of TANCoV1.3.20 SARS _CoV-2 vaccine among healthy participants in Tanzania.
Sayoki Mfinanga
NIMR Mbeya
Government of the United Republic of Tanzania.
TZS 600,000,000
2022-2024
36
The African Cohort study
Lucas Maganga
NIMR Mbeya
US Military HIV Research Program/WRAIR
USD 850,000 annually
2013-2027
37
Mobile Diagnostic and Training Centre (MDTC)
Lucas Maganga
NIMR Mbeya.
Walter Reed (HJFMRI) Southern Highlands HIV Care Programme
USD 300,000
Oct 2022 – Sep 2024
38
A multicenter, phase III, double-blind, randomized, active-controlled study to evaluate the efficacy and safety of VPM1002 in comparison to BCG in prevention of Mycobacterium tuberculosis infection in newborn infants.
Issa Sabi
NIMR Mbeya
Serum Institute of India, Limited (SIIPL)
Euro 950,348.50
Aug 2021 to Aug 2024
39
Early risk assessment in TB contacts by new diagnostic tests
Lilian Minja
NIMR Mbeya
EDCTP
Euro 735,393
2021- 2024
40
On-treatment study embedded within the early risk assessment in TB contacts by new diagnostic tests and other sub-studies
Lilian Minja
NIMR Mbeya
EDCTP
Euro 206,714
Q4 2021-Q1 2025
41
A randomized double-blind placebo-controlled trial of Rifapentine and Isoniazid for prevention of Tuberculosis in people with diabetes
Elias Nyanda
NIMR Mbeya
EDCTP
Euro 1,374,830
Jan 2020 – Dec 2027
42
A Phase 4 operational study to assess the effectiveness, feasibility, acceptability, and cost effectiveness of implementing the GeneXpert MTB/XDR (Xpert XDR; Cepheid) assay for rapid triage-and-treatment of DR-TB. A multi-centre, multi-country prospective cohort study
Elias Nyanda
NIMR Mbeya
EDCTP2
Euro 287,556.25
Jan 2021 – Dec 2024
43
Molbio TruenatTM TB platform combined with the Truenat TB assays for detection of Tuberculosis and Rifampicin-resistance in adults with presumptive Pulmonary Tuberculosis at primary-level diagnostic centres in Tanzania and Mozambique: A pragmatic, cluster- randomized controlled trial
Elias Nyanda
NIMR Mbeya
EDCTP
Euro 450,000
2020 – 2024
44
Expanding Xpert Ultra testing for TB diagnosis among HIV-positive patients admitted to hospital in Tanzania and Mozambique
Elias Nyanda
NIMR Mbeya
Euro 450,000
2020 – Nov 2024
45
Dynamic clinical decision support algorithms to manage sick children in primary health care settings in Tanzania (DYNAMIC TZ)
Elias Nyanda
NIMR Mbeya
Botnar Foundation through Swiss Tropical and Public Health Institute, (Swiss TPH)
CHF 1,105,512.50
Apr 2019 – September 2024
46
A Randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of Inclacumab in participants with Sickle Cell Disease experiencing vaso-occlusive crises
Issa Sabi
NIMR Mbeya
Global Blood Therapeutics, Inc
USD 62,700
Jan 2021 – December 2024
47
Community and Universal testing for TB among contacts
Elias Nyanda
NIMR Mbeya
EDCTP
Euro 664,809
Dec 2021 – Dec 2024
48
Evaluation of the Tuberculosis Molecular Bacterial Load Assay (TB-MBLA) Research Use Only (RUO) Kit for the Diagnosis and Monitoring of Treatment Response using Sputum of Symptomatic Adult Patients with Pulmonary TB.
Elias Nyanda
NIMR Mbeya
Life Arc
$240,971
Jan 2023 – Aug 2024